2024
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Dutta R, Thibaud S, Leshchenko V, Ram M, Melnekoff D, Bhalla S, Restrepo P, Gupta V, Barwick B, Newman S, McCafferty J, Hantash F, Nooka A, Cho H, Richard S, Rodriguez C, Rossi A, Sanchez L, Chari A, Boise L, Jagannath S, Richter J, Parekh S, Laganà A. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. Blood Neoplasia 2024, 1: 100049. DOI: 10.1016/j.bneo.2024.100049.Peer-Reviewed Original ResearchCyclin-dependent kinase 7Progression-free survivalMultiple myelomaAnalysis of RNA-seq dataMM cellsTherapeutic strategiesPatients treated with venetoclaxCDK7 inhibitor THZ1Overcome venetoclax resistanceRNA-seq dataSix-gene signaturePredictors of responseChromosome 1q gainPersonalized therapeutic strategiesDevelopment of personalized therapeutic strategiesInduce cell deathMarkers of sensitivityBCL2 inhibitorsCDK7 inhibitionMCL1 genePrognostic importanceStratify patientsCyclin-dependentMCL1 levelsPatient population
2023
Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
Chatur S, Vaduganathan M, Claggett B, Desai A, Docherty K, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mcmurray J, Solomon S. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: ehad655.751. DOI: 10.1093/eurheartj/ehad655.751.Peer-Reviewed Original ResearchUrgent HF visitsHeart failureHF eventsHF hospitalizationHF visitsEjection fractionFirst presentationSubsequent mortalityComposite endpointSubsequent deathEffect of dapagliflozinTreatment effectsBackground HospitalizationCV causesCV deathDose uptitrationPrimary endpointPrognostic importanceClinical trialsFirst manifestationLandmark analysisAmbulatory careHospitalizationClinical relevancePatientsAssociation of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure
Rao V, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Testani J. Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure. Journal Of Cardiac Failure 2023, 30: 340-346. PMID: 37301248, PMCID: PMC10947725, DOI: 10.1016/j.cardfail.2023.05.018.Peer-Reviewed Original ResearchGalectin-3 levelsHeart failureGalectin-3Renal fibrosisCardiac Function Heart FailureAldosterone Antagonist TrialContemporary HF cohortChronic kidney diseaseGlomerular filtration rateLow-risk phenotypeSignificant effect modificationLower eGFR levelsRenal tissue fibrosisAmino-terminal propeptideType III procollagenCardiorenal dysfunctionCardiorenal outcomesTOPCAT studyCause mortalityHF cohortSerum creatinineClinic cohortPrognostic importanceKidney diseasePrognostic indicatorImprovement in Renal Function During the Treatment of Acute Decompensated Heart Failure: Relationship With Markers of Renal Tubular Injury and Prognostic Importance
Natov P, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Maulion C, Bellumkonda L, Shlipak M, Estrella M, Borlaug B, Rao V, Testani J. Improvement in Renal Function During the Treatment of Acute Decompensated Heart Failure: Relationship With Markers of Renal Tubular Injury and Prognostic Importance. Circulation Heart Failure 2023, 16: e009776. PMID: 36700431, PMCID: PMC10150783, DOI: 10.1161/circheartfailure.122.009776.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureStable renal functionGlomerular filtration rateRenal functionRenal tubular injuryHeart failureTubular injuryKIM-1Filtration rateRenal tubular injury markersTubular injury markersRenal function groupCumulative urine outputCardiorenal dysfunctionDiuretic dosesInjury markersWorse survivalWorsened survivalUrine outputDecongestive therapyPrognostic importanceAdverse outcomesLower admissionPatients
2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Pollyea D, Bixby D, Perl A, Bhatt V, Altman J, Appelbaum F, de Lima M, Fathi A, Foran J, Gojo I, Hall A, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin M, Mims A, Neff J, Nejati R, Olin R, Percival M, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami P, Stone R, Strickland S, Sweet K, Vachhani P, Wieduwilt M, Gregory K, Ogba N, Tallman M. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 16-27. PMID: 33406488, DOI: 10.6004/jnccn.2021.0002.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaNCCN GuidelinesFavorable-risk acute myeloid leukemiaLow-risk acute promyelocytic leukemiaVenetoclax-based therapyNCCN Guidelines InsightsClinical decision-makingTreatment of adultsAcute promyelocytic leukemiaPrognostic importanceBlood transfusionMyeloid leukemiaGenetic alterationsTreatment strategiesClinical trialsPromyelocytic leukemiaNCCNLeukemiaTreatmentGuidelinesDecision-makingPhysiciansPostremissionTransfusionTherapy
2020
An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status
Ahluwalia M, Ali MA, Joshi RS, Park ES, Taha B, McCutcheon I, Chiang V, Hong A, Sinclair G, Bartek J, Chen CC. An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status. Neuro-Oncology Advances 2020, 3: vdaa152. PMID: 33506199, PMCID: PMC7810198, DOI: 10.1093/noajnl/vdaa152.Peer-Reviewed Original ResearchCumulative intracranial tumor volumeNumber of metastasesBRAF mutation statusMelanoma brain metastasesBrain metastasesStereotactic radiosurgeryMutation statusPrognostic scalesMelanoma patientsSurvival prognosticationIndependent cohortMultivariate Cox proportional hazards modelCox proportional hazards modelIntracranial tumor volumePrognostic assessment scaleMulti-institutional collaborationNet reclassification indexProportional hazards modelBM patientsMainstay therapyPatient characteristicsTumor characteristicsPrognostic importancePrognostic utilityReclassification index
2019
Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition
Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncology 2019, 99: 104447. PMID: 31630059, DOI: 10.1016/j.oraloncology.2019.104447.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaExtranodal extensionLymphovascular invasionKaplan-Meier overall survival analysisContralateral lymph node involvementHPV-positive oropharyngeal cancerFuture staging systemsNational Cancer DatabaseLymph node involvementLymph nodal involvementSquamous cell carcinomaAJCC eighth editionOverall survival analysisPathologic nodalInferior OSNodal involvementNode involvementWorse OSClinical stagingPrognostic factorsOropharyngeal cancerPositive marginsPrognostic importanceCell carcinomaCox regressionPSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
Halabi S, Dutta S, Chi K, Tangen C, Xuan M, Petrylak D, Araujo J, Fizazi K, Quinn D, Morris M, Higano C, Tannock I, Small E, Kelly W. PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2019, 37: 5021-5021. DOI: 10.1200/jco.2019.37.15_suppl.5021.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerObjective response rateCastration-resistant prostate cancerPSA declinePercentage of patientsPooled odds ratioMultivariable analysisAsian menAA menOdds ratioProstate cancerResponse ratePhase III clinical trialsPhase III trialsResistant prostate cancerSite of metastasisIndividual patient dataLogistic regression modelsMeasurable diseaseIII trialsPerformance statusTreatment armsPrognostic importanceC menRisk factorsClinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
Halabi S, Dutta S, N. K, Tangen C, Petrylak D, Araujo J, Fizazi K, Quinn D, Higano C, Tannock I, Small E, Kelly W. Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2019, 37: 186-186. DOI: 10.1200/jco.2019.37.7_suppl.186.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPSA progression-free survivalProgression-free survivalCastration-resistant prostate cancerPooled hazard ratioMultivariable analysisAsian menHazard ratioProstate cancerMedian PSA progression-free survivalAfrican AmericansMedian progression-free survivalPhase III clinical trialsPhase III trialsResistant prostate cancerIndividual patient dataProportional hazards modelAfrican American menIII trialsPFS outcomesPrognostic factorsClinical outcomesPrognostic importanceTreatment armsCaucasian man
2018
Clinical Utility and Prognostic Value of Right Atrial Function in Pulmonary Hypertension
Alenezi F, Mandawat A, Il'Giovine ZJ, Shaw LK, Siddiqui I, Tapson VF, Arges K, Rivera D, Romano MMD, Velazquez EJ, Douglas PS, Samad Z, Rajagopal S. Clinical Utility and Prognostic Value of Right Atrial Function in Pulmonary Hypertension. Circulation Cardiovascular Imaging 2018, 11: e006984. PMID: 30571314, PMCID: PMC6309911, DOI: 10.1161/circimaging.117.006984.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionArterial hypertensionRA dysfunctionLongitudinal strainComplete echocardiographic dataResults Study subjectsRight atrial functionRight atrial enlargementComposite of timeEarly diastolic SRPeak longitudinal strainRA conduitRA reservoirMultivariable adjustmentPulmonary hypertensionAtrial functionComposite outcomeDiastolic SRAtrial enlargementAtrial sizePrimary outcomePrognostic importancePrognostic valueAdverse outcomesMean ageOverall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).
Halabi S, Dutta S, Tangen C, Rosenthal M, Petrylak D, Thompson I, Chi K, De Bono J, Fandi A, Araujo J, Eisenberger M, Logothetis C, Quinn D, Fizazi K, Higano C, George D, Morris M, Small E, Tannock I, Kelly W. Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2018, 36: lba5005-lba5005. DOI: 10.1200/jco.2018.36.18_suppl.lba5005.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerDocetaxel/prednisoneOverall survivalCaucasian manHazard ratioLymph nodesRisk factorsProstate cancerMedian overall survivalPerformance status 0Phase III trialsPooled hazard ratioShorter overall survivalIndividual patient dataProportional hazards modelAfrican American menStatus 0Primary endpointIII trialsMedian hemoglobinMedian ageLiver diseaseMultivariable analysisPrognostic importance“Getting beyond diameter”: when to replace the aorta?
Tanweer M, Zafar M, Saeyeldin A, Gryaznov A, Puddifant A, Erben Y, Ziganshin B, Elefteriades J. “Getting beyond diameter”: when to replace the aorta? Journal Of Visualized Surgery 2018, 4: 124-124. DOI: 10.21037/jovs.2018.06.04.Peer-Reviewed Original ResearchAortic sizeThoracic aortic aneurysm patientsProgression of TAAAortic aneurysm patientsTimely surgical interventionBody surface areaProphylactic surgical repairSpecific genetic mutationsUse of biomarkersAdvanced imaging techniquesAortic surgeryAortic dissectionSurgical treatmentCatastrophic complicationSurgical repairPrognostic importancePrognostic significanceSurgical interventionAneurysm patientsTAA patientsPatient heightDisease progressionFamily historyFemale genderAnatomical aberrations
2016
Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis
Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiology 2016, 1: 880-889. PMID: 27557400, DOI: 10.1001/jamacardio.2016.2839.Peer-Reviewed Original ResearchConceptsATTR cardiac amyloidosisCardiac amyloidosisMulticenter studyWorse survivalEjection fractionHeart failureCardiac imagingMultivariable Cox proportional hazards regression analysisCox proportional hazards regression analysisProportional hazards regression analysisRetrospective cohort studyHigh clinical suspicionSingle-center studyHazards regression analysisKaplan-Meier analysisAL cardiac amyloidosisDifferentiation of patientsTransthyretin cardiac amyloidosisDates of analysisSemiquantitative visual scoreContralateral chestPlanar technetiumClinical suspicionCohort studyPrognostic importanceThe Prognostic Importance of Pathologic Extracapsular Extension in Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma
An Y, Park H, Kelly J, Stahl J, Contessa J, Husain Z. The Prognostic Importance of Pathologic Extracapsular Extension in Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e346. DOI: 10.1016/j.ijrobp.2016.06.1500.Peer-Reviewed Original ResearchSlow Gait Speed and Risk of Mortality or Hospital Readmission After Myocardial Infarction in the Translational Research Investigating Underlying Disparities in Recovery from Acute Myocardial Infarction: Patients' Health Status Registry
Dodson JA, Arnold SV, Gosch KL, Gill TM, Spertus JA, Krumholz HM, Rich MW, Chaudhry SI, Forman DE, Masoudi FA, Alexander KP. Slow Gait Speed and Risk of Mortality or Hospital Readmission After Myocardial Infarction in the Translational Research Investigating Underlying Disparities in Recovery from Acute Myocardial Infarction: Patients' Health Status Registry. Journal Of The American Geriatrics Society 2016, 64: 596-601. PMID: 26926309, PMCID: PMC4803531, DOI: 10.1111/jgs.14016.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionSlow gaitHospital readmissionGait speedOlder adultsCox proportional hazards regressionMarker of frailtySlow gait speedTranslational researchProportional hazards regressionOutcomes 1 yearRisk of mortalityAssessment 1 monthBaseline characteristicsObservational cohortClinical factorsDiabetes mellitusHeart failureHazards regressionPrognostic importancePrognostic valueHigh prevalenceInfarctionReadmissionHypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure
Testani JM, Hanberg JS, Arroyo JP, Brisco MA, Ter Maaten JM, Wilson FP, Bellumkonda L, Jacoby D, Tang WH, Parikh CR. Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. European Journal Of Heart Failure 2016, 18: 660-668. PMID: 26763893, PMCID: PMC5471359, DOI: 10.1002/ejhf.477.Peer-Reviewed Original ResearchConceptsChronic heart failureHeart failureSerum chlorideSerum sodiumLow serum sodiumHeart failure pathophysiologyGreater disease severityBEST trialDiuretic dosesSerum chloride valuesRenal functionWorsened survivalPrognostic importanceAdverse outcomesUnivariate analysisHyponatraemiaHypochloraemiaPatientsDisease severityMortalityAdditional researchFailureChloride valuesCritical roleSodium
2015
Current state of prognostication and risk stratification in myelodysplastic syndromes
Zeidan AM, Gore SD, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes. Current Opinion In Hematology 2015, 22: 146-154. PMID: 25575032, DOI: 10.1097/moh.0000000000000110.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2013
Prevalence and Prognostic Importance of Changes in Renal Function After Mechanical Circulatory Support
Brisco MA, Kimmel SE, Coca SG, Putt ME, Jessup M, Tang WW, Parikh CR, Testani JM. Prevalence and Prognostic Importance of Changes in Renal Function After Mechanical Circulatory Support. Circulation Heart Failure 2013, 7: 68-75. PMID: 24214901, PMCID: PMC4067252, DOI: 10.1161/circheartfailure.113.000507.Peer-Reviewed Original ResearchConceptsMechanical circulatory supportRenal functionCirculatory supportEarly improvementContinuous-flow devicesMechanically Assisted Circulatory SupportLarge multicenter populationSerial creatinine levelsGlomerular filtration rateMajority of patientsMulticenter populationCause mortalityInteragency RegistryAdult patientsCreatinine levelsPrognostic importancePrognostic significanceImproved prognosisFiltration ratePoor survivalSurvival disadvantageEGFRPatientsAdditional researchMechanistic basisInfluence of Age-Related Versus Non–Age-Related Renal Dysfunction on Survival in Patients With Left Ventricular Dysfunction
Testani JM, Brisco MA, Han G, Laur O, Kula AJ, Cheng SJ, Tang WH, Parikh CR. Influence of Age-Related Versus Non–Age-Related Renal Dysfunction on Survival in Patients With Left Ventricular Dysfunction. The American Journal Of Cardiology 2013, 113: 127-131. PMID: 24216124, PMCID: PMC3915785, DOI: 10.1016/j.amjcard.2013.09.029.Peer-Reviewed Original ResearchConceptsLow glomerular filtration rateGlomerular filtration rateVentricular dysfunctionRenal dysfunctionNormal agingLeft ventricular dysfunctionRisk of deathNormal aging resultsAge-related decreaseInfluence of ageBaseline eGFRMean eGFRLower eGFRWorsened survivalPrognostic importanceFiltration rateSurvival disadvantagePrimary analysisDysfunctionEGFRSignificant riskPatientsUnderlying mechanismRiskMortalityParotid gland lymphoma: Prognostic analysis of 2140 patients
Feinstein AJ, Ciarleglio MM, Cong X, Otremba MD, Judson BL. Parotid gland lymphoma: Prognostic analysis of 2140 patients. The Laryngoscope 2013, 123: 1199-1203. PMID: 23576299, DOI: 10.1002/lary.23901.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAgedAged, 80 and overChildChild, PreschoolDisease-Free SurvivalFemaleHumansIncidenceInfantInfant, NewbornKaplan-Meier EstimateLymphomaMaleMiddle AgedParotid NeoplasmsPrognosisProportional Hazards ModelsRetrospective StudiesSEER ProgramSex DistributionSurvival RateUnited StatesYoung AdultConceptsParotid gland lymphomaFacial nerve sacrificeB-cell lymphomaNerve sacrificeHodgkin's lymphomaMarginal zone B-cell lymphomaEnd Results Program databaseKaplan-Meier survival curvesCox proportional hazards modelNon-Hodgkin lymphoma subtypesLarge B-cell lymphomaUS population-based dataRetrospective cohort studyRole of chemotherapyLog-rank testPopulation-based dataForm of surgeryProportional hazards modelCohort studyPatient agePathologic featuresPrognostic importanceMale genderProgram databaseLymphoma subtypes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply